KLRA Stock Forecast: Kailera Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Kailera Therapeutics, Inc. is $44. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Kailera Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (57): Analysts have, on balance, been raising their forecasts.
Volatility (4): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
KLRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on KLRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Canaccord Genuity | Initiates | Buy | $44 |
| 12 May 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 12 May 2026 | Jefferies | Initiates | Buy | $48 |
| 12 May 2026 | JP Morgan | Initiates | Overweight | $30 |
| 12 May 2026 | Leerink Partners | Initiates | Outperform | $36 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for KLRA.
This page is one stock. Monday covers all of them.
KLRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
KLRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
KLRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 1.4×
- EV / EBITDA
- —
Cheaper than 57% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −21.5%
- Dividend yield
- —
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kailera Therapeutics, Inc. has a market value of $1.4B and an enterprise value of $612.2M.
Kailera Therapeutics, Inc. employs 145 people.
Data provided by Twelve Data
KLRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at KLRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Kailera Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about KLRA
What is the KLRA stock price forecast for 2026-2027?
The median 12-month analyst price target for Kailera Therapeutics, Inc. is $44, with estimates ranging from $30 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is KLRA stock a buy right now?
Of the 7 analysts covering Kailera Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kailera Therapeutics, Inc. 3 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank KLRA?
As at 21 Nov 2026, Kailera Therapeutics, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (57 of 100).
Will KLRA stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts is $44, and Ticker Nerd's factor model ranks Kailera Therapeutics, Inc. 3 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the KLRA stock forecast for 2030?
No analyst covering Kailera Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KLRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $57 over the next 12 months.
What does Kailera Therapeutics, Inc. do?
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for obesity and related metabolic conditions. Kailera Therapeutics advances a diversified pipeline of injectable and oral product candidates built around GLP-1-based mechanisms, including programs that target GLP-1, GIP, and glucagon pathways.
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for obesity and related metabolic conditions. Kailera Therapeutics advances a diversified pipeline of injectable and oral product candidates built around GLP-1-based mechanisms, including programs that target GLP-1, GIP, and glucagon pathways. Its portfolio is designed to address different patient needs in obesity care through multiple routes of administration and varying dosing approaches. The company’s lead program, ribupatide, is a once-weekly injectable GLP-1/GIP dual agonist being evaluated in late-stage clinical development. Kailera Therapeutics also works on oral small-molecule and peptide candidates that expand its treatment options across the weight-management market. Based in Waltham, Massachusetts, Kailera Therapeutics serves the biotechnology and metabolic disease sectors with a focus on modern obesity care.
CEO Mr. Ronald C. Renaud Jr., M.B.A. · 145 employees · United States · https://www.kailera.com